Hypercholesterolemic patients with cognitive dysfunction
Conditions
Interventions
Pitavastatin Calcium(LIVALO) Taking a dose of 1-4mg once daily. Daily dose is determined based on Japan Atherosclerosis Society Guidelines 2012 for Prevension of Atherosclerotic Cardiovascular Diseas
Sponsors
Department of Geriatric Medicine, Kyorin University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Outpatients of Kyorin University Hospital Amnesia Center Judged that a lipid-lower therapy is required by Japan Atherosclerosis Society Guidelines 2012 for Prevention of Atherosclerotic Cardiovascular Diseases over 65 years old. 2.Patients who receive any statin can entry after 4 weeks washout periods. 3.the mild cognitive impairment to dementia patients.(15<=MMSE<=30) 4.PVH grade >=1/4 or DWMH grade >=1/4 (judged by two or more doctors) 5.Written informed consent is obtained from subjects or their family relatives or legally acceptable representatives before entry.
Exclusion criteria
Exclusion criteria: 1.History of hypersensitivity to any of the ingredients of the product. 2.Severe hepatic disorder or biliary atresia. 3.Receiving cyclosporine. 4.Patients receiving fibrates who also have laboratory evidence of abnormal renal function. 5.Individuals who are ineligible in the opinion of the physician in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| .Change of cerebral white matter lesions(MRI) .Change of arteriosclerosis marker(PWV, IMT) .Change of cognitive function(MMSE) .Change of cerebral blood flow(SPECT) .Change of serum lipids | — |
Countries
Japan
Contacts
Public ContactYukiko Moriya
Kyorin University School of Medicine Department of Geriatric Medicine
Outcome results
None listed